Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (471)	6/25/2007 3:43:39 PM
From: tuck	Respond to of 523

Also worth noting is that they intend to partner NG-273 at the beginning of the P3 program, or very early into it, and that they hope to start P3 by the end of next year. Amnesia seen mostly at the two highest doses. So expect to see middling doses and formulation "A" taken forward. PK/PD data still undergoing analysis, should be released in a few weeks. Cheers, Tuck

To: tuck who wrote (471)	6/25/2007 5:51:54 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 523

I own some nrgn but I don't feel particularly 'up on it'. That is a sad admission, true. (For example, I had no idea the obesity trial--did you say--was stopped by dsmb????) Agree with you, seems sleep programs everywhere are not worth nearly as much as they were before all of the circumstances of lunesta, indiplon and generic ambien occured. Companies in the space probably won't get credit for them until they hit the market.